Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc

This study has been completed.
Sponsor:
Collaborators:
Aaron Diamond AIDS Research Center
Pfizer
Information provided by (Responsible Party):
Rockefeller University
ClinicalTrials.gov Identifier:
NCT00703586
First received: June 19, 2008
Last updated: October 22, 2012
Last verified: October 2012

June 19, 2008
October 22, 2012
September 2007
May 2011   (final data collection date for primary outcome measure)
MMC HIV RNA [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00703586 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc
A Two-Arm, Single Site, Proof of Concept Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc, a CCR5 Antagonist (ADARC 2007-02)

Hypothesis: Intensification of current ARV regimens with maraviroc will result in more complete suppression of viral replication, particularly in the gastrointestinal mucosa with resultant reduction in markers of immune activation and improved GI immune reconstitution.

  • DURATION: Subjects will participate for a minimum of 28 weeks.
  • SAMPLE SIZE: 18 subjects randomized 2:1 continued ARVs plus maraviroc versus continued ARVs plus additional ARV to be determined based on baseline ARV regimen.
  • REGIMEN: At entry, subjects will be randomized to one of the following in a 2:1 ratio:

ARM A:

Intensification with maraviroc for 24 weeks at one of the following doses:

  • 150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor
  • 600 mg orally BID when coadministered with efavirenz or nevirapine

ARM B

Intensification with an additional NRTI for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:

  • Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc
  • Addition of an alternate FDA approved NRTI [such as zidovudine (AZT) or didanosine (ddi)] at standard oral dosing to a tenofovir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.

The objectives of this study are:

To determine whether intensification of current ARV regimens with maraviroc will result in more complete suppression of viral replication and improved immune reconstitution in GI mucosal lymphoid compartment based on:

  • Reduction in normalized levels of CD4+MMC HIV-1 RNA as determined by PCR pre- and post- intensification at week 12 in Arm A versus Arm B.
  • Reduction in normalized levels of CD4+ mucosal mononuclear cell (MMC) HIV-1 RNA at week 12 compared to baseline in Arm A.
  • Reduction in %CD4+MMC HIV-1 RNA positive as determined by PCR pre- and post- intensification between Arm A and Arm B as well as week 12 and 24 post maraviroc intensification.
  • Levels of CD4+ T cells in GALT (% by flow and absolute #s by immunohistochemistry).
  • Phenotype of cells in GALT by flow (memory, naive, R5, X4, dual expressing).
  • Levels of activation of CD4 and CD8 in PB and GALT using HLA DR and CD 38.
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
HIV Infections
Drug: Maraviroc

ARM A:

Addition of maraviroc to baseline ARV medications for 24 weeks at one of the following doses:

  • 150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor
  • 600 mg orally BID when coadministered with efavirenz or nevirapine

ARM B:

Addition of an additional NRTI to baseline ARV medications for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:

  • Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc.
  • Addition of an alternate FDA approved NRTI [such as zidovudine (AZT) or didanosine (ddi)] at standard oral dosing to a tenofir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.
  • Addition of tenofovir 300 mg daily to an abacavir containing regimen for 12 weeks then replacing the tenofovir with maraviroc.
  • Experimental: 1

    ARM A:

    Intensification with maraviroc for 24 weeks at one of the following doses:

    • 150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor
    • 600 mg orally BID when coadministered with efavirenz or nevirapine
    Intervention: Drug: Maraviroc
  • Active Comparator: 2

    ARM B

    Intensification with an additional NRTI for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:

    • Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc
    • Addition of an alternate FDA approved NRTI [such as zidovudine (AZT) or didanosine (ddi)] at standard oral dosing to a tenofovir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.
    Intervention: Drug: Maraviroc
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
8
May 2011
May 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Documented treatment with combination antiviral therapy (ARV) during acute and early HIV-1 infection defined as:

    • Negative ELISA/Western Blot or indeterminate Western Blot in the presence of HIV-1 RNA>5,000 copies/ml
    • Positive HIV-1 serology with a detuned ELISA O.D. value below 1.0
    • A documented negative serology within 180 days of screening and a positive HIV-1 serology at screening
  • Treatment for at least one year with ARVs
  • Plasma HIV-1 RNA levels below detection for at least 6 months
  • CCR5 tropic virus pretreatment using the Monogram assay
  • GI biopsy at study entry
  • Agree to subsequent GI biopsy at 12 and 24 weeks
  • Laboratory values obtained within 45 days prior to study entry.

    • Absolute neutrophil count (ANC) ≥500/mm³
    • Hemoglobin ≥9.0 g/dL
    • Platelet count ≥80,000/mm³
    • AST (SGOT), ALT (SGPT), and alkaline phosphatase < 5.0 x ULN
    • Total bilirubin ≤ 2.5 X ULN if not on atazanavir containing regimen
    • PT/PTT within 1.5 control
    • Calculated creatinine clearance ≥60 mL/min as estimated by the Cockcroft Gault equation:
    • For men, (140 - age in years) x (body weight in kg) / (serum creatinine in mg/dL x 72) = CrCl (mL/min)
    • For women, multiply the result by 0.85 = CrCl (mL/min) NOTE: A program to assist in calculations is available on the DMC web site at: http://www.fstrf.org/ACTG/ccc.html
  • For women of reproductive potential, negative serum or urine pregnancy test within 48 hours prior to initiating study medications unless otherwise specified by product labeling.
  • Female candidates of reproductive potential is defined as girls who have reached menarche or women who have not been post-menopausal for at least 24 consecutive months (i.e., who have had menses within the preceding 24 months) or have not undergone surgical sterilization (e.g., hysterectomy, or bilateral oophorectomy, or bilateral tubal ligation).
  • Contraception requirements:

    • Female candidates of reproductive potential, who are participating in sexual activity that could lead to pregnancy, must agree that they will use at least one reliable method of contraception while receiving the protocol-specified drugs and for 6 weeks after stopping the medications.
    • Male Candidates: If you are a heterosexual male, you and your sexual partner must agree to use acceptable methods of birth control during the entire study. Acceptable methods of birth control include intrauterine device (IUD), diaphragm with spermicide,condoms or not having sex. Oral contraceptives alone are not an acceptable method of birth control.
  • Men and women age ≥18 years.
  • Participants must be HLA-B5701 negative if not taking abacavir as part of their regimen.
  • Ability and willingness of subject to give written informed consent.

Exclusion Criteria:

  • Currently breast-feeding.
  • Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy within 30 days prior to study entry. NOTE: Subjects receiving stable physiologic glucocorticoid doses, defined as prednisone ≤ 10 mg/day, will not be excluded.
  • Known allergy/sensitivity to study drugs or their formulations.
  • Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  • Serious illness requiring systemic treatment and/or hospitalization until candidate either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 7 days prior to study entry.
  • Pretreatment viral population that is either dual mixed tropic or X4 tropic using the Monogram assay
  • Current imprisonment or involuntary incarceration in a medical facility for psychiatric or physical (e.g., infectious disease) illness.
  • Any other clinical conditions or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the requirements.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00703586
MMA-0612
No
Rockefeller University
Rockefeller University
  • Aaron Diamond AIDS Research Center
  • Pfizer
Principal Investigator: Martin Markowitz, MD Rockefeller University
Rockefeller University
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP